5/13
08:09 am
ocs
Oculis Holding AG (NASDAQ: OCS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
Neutral
Report
Oculis Holding AG (NASDAQ: OCS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
5/8
04:23 pm
ocs
Oculis Reports Q1 2024 Financial Results and Provides Company Updates [Yahoo! Finance]
Medium
Report
Oculis Reports Q1 2024 Financial Results and Provides Company Updates [Yahoo! Finance]
5/8
04:23 pm
ocs
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis [Yahoo! Finance]
Medium
Report
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis [Yahoo! Finance]
5/8
04:10 pm
ocs
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
Medium
Report
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
5/8
04:05 pm
ocs
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
Medium
Report
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
5/6
06:30 am
ocs
Oculis to Present at Bank of America Global Healthcare Conference
Low
Report
Oculis to Present at Bank of America Global Healthcare Conference
4/29
04:05 pm
ocs
Oculis Publishes Invitation to the Annual General Meeting
Low
Report
Oculis Publishes Invitation to the Annual General Meeting
4/24
08:10 am
ocs
Oculis Holding AG (NASDAQ: OCS) had its price target lowered by analysts at HC Wainwright from $29.00 to $28.00. They now have a "buy" rating on the stock.
Low
Report
Oculis Holding AG (NASDAQ: OCS) had its price target lowered by analysts at HC Wainwright from $29.00 to $28.00. They now have a "buy" rating on the stock.
4/22
09:27 am
ocs
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
Low
Report
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
4/22
08:47 am
ocs
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market [Yahoo! Finance]
Low
Report
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market [Yahoo! Finance]
4/11
09:07 am
ocs
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market [Yahoo! Finance]
Low
Report
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market [Yahoo! Finance]
4/11
08:55 am
ocs
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
Low
Report
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
4/10
06:30 am
ocs
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
Medium
Report
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
4/8
06:33 am
ocs
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting [Yahoo! Finance]
Medium
Report
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting [Yahoo! Finance]
4/8
06:30 am
ocs
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Medium
Report
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
4/4
06:30 am
ocs
Oculis to Participate at Upcoming April Investor Conferences
Medium
Report
Oculis to Participate at Upcoming April Investor Conferences
3/19
09:31 am
ocs
Oculis Holding AG (NASDAQ: OCS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock.
Low
Report
Oculis Holding AG (NASDAQ: OCS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $30.00 price target on the stock.
3/19
08:08 am
ocs
Oculis Holding AG (NASDAQ: OCS) had its price target lowered by analysts at Robert W. Baird from $64.00 to $35.00. They now have an "outperform" rating on the stock.
Low
Report
Oculis Holding AG (NASDAQ: OCS) had its price target lowered by analysts at Robert W. Baird from $64.00 to $35.00. They now have an "outperform" rating on the stock.
3/18
06:35 am
ocs
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress [Yahoo! Finance]
Medium
Report
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress [Yahoo! Finance]
3/18
06:30 am
ocs
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
Medium
Report
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
3/6
11:58 am
ocs
Oculis Holding AG (NASDAQ: OCS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock.
Low
Report
Oculis Holding AG (NASDAQ: OCS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock.
2/29
09:10 am
ocs
Oculis Holding AG (NASDAQ: OCS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
Medium
Report
Oculis Holding AG (NASDAQ: OCS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.
2/28
06:38 am
ocs
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments [Yahoo! Finance]
Medium
Report
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments [Yahoo! Finance]
2/28
06:30 am
ocs
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments
Medium
Report
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments